6.
Inkster J, Akurathi V, Sromek A, Chen Y, Neumeyer J, Packard A
. A non-anhydrous, minimally basic protocol for the simplification of nucleophilic F-fluorination chemistry. Sci Rep. 2020; 10(1):6818.
PMC: 7176689.
DOI: 10.1038/s41598-020-61845-y.
View
7.
Seeman P
. Are dopamine D2 receptors out of control in psychosis?. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46:146-52.
DOI: 10.1016/j.pnpbp.2013.07.006.
View
8.
Orlovskaya V, Antuganov D, Fedorova O, Timofeev V, Krasikova R
. Tetrabutylammonium tosylate as inert phase-transfer catalyst: The key to high efficiency S2 radiofluorinations. Appl Radiat Isot. 2020; 163:109195.
DOI: 10.1016/j.apradiso.2020.109195.
View
9.
van Wieringen J, Booij J, Shalgunov V, Elsinga P, Michel M
. Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol. 2012; 386(2):135-54.
DOI: 10.1007/s00210-012-0817-0.
View
10.
Basuli F, Zhang X, Woodroofe C, Jagoda E, Choyke P, Swenson R
. Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination. J Labelled Comp Radiopharm. 2016; 60(3):168-175.
PMC: 5344719.
DOI: 10.1002/jlcr.3487.
View
11.
Orlovskaya V, Fedorova O, Nadporojskii M, Krasikova R
. A fully automated azeotropic drying free synthesis of O-(2-[F]fluoroethyl)-l-tyrosine ([F]FET) using tetrabutylammonium tosylate. Appl Radiat Isot. 2019; 152:135-139.
DOI: 10.1016/j.apradiso.2019.07.006.
View
12.
Seeman P
. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Synapse. 2007; 61(12):1013-8.
DOI: 10.1002/syn.20453.
View
13.
Sergeev M, Morgia F, Lazari M, Wang Jr C, van Dam R
. Titania-catalyzed radiofluorination of tosylated precursors in highly aqueous medium. J Am Chem Soc. 2015; 137(17):5686-94.
PMC: 4485375.
DOI: 10.1021/jacs.5b02659.
View
14.
Sokoloff P, Giros B, Martres M, Bouthenet M, Schwartz J
. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990; 347(6289):146-51.
DOI: 10.1038/347146a0.
View
15.
Narendran R, Hwang D, Slifstein M, Hwang Y, Huang Y, Ekelund J
. Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [11C]N-propyl-norapomorphine and [11C]raclopride in baboons. J Pharmacol Exp Ther. 2005; 315(1):80-90.
DOI: 10.1124/jpet.105.090068.
View
16.
Si Y, Gardner M, Tarazi F, Baldessarini R, Neumeyer J
. Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. Bioorg Med Chem Lett. 2008; 18(14):3971-3.
DOI: 10.1016/j.bmcl.2008.06.016.
View
17.
Hartvig P, Eckernas S, Ekblom B, Lindstrom L, Lundqvist H, Axelsson S
. Receptor binding and selectivity of three 11C-labelled dopamine receptor antagonists in the brain of rhesus monkeys studied with positron emission tomography. Acta Neurol Scand. 1988; 77(4):314-21.
DOI: 10.1111/j.1600-0404.1988.tb05915.x.
View
18.
Breier A, Su T, Saunders R, Carson R, Kolachana B, de Bartolomeis A
. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997; 94(6):2569-74.
PMC: 20129.
DOI: 10.1073/pnas.94.6.2569.
View
19.
Blum K, Sheridan P, Wood R, Braverman E, Chen T, Cull J
. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996; 89(7):396-400.
PMC: 1295855.
DOI: 10.1177/014107689608900711.
View
20.
Beaulieu J, Gainetdinov R
. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 63(1):182-217.
DOI: 10.1124/pr.110.002642.
View